Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The clinical study using a sub-therapeutic dose of a GnRH antagonist to reduce overactive LH
pulsatility in women with PCOS. With the intervention and lowered LH action we anticipate to
decrease androgen levels in women with PCOS. The aim to show for the first time that low-dose
GnRH-antagonists can lower LH pulsatility by 20-30% and decrease androgen levels without
blunting the hypothalamic-pituitary-gonadal axis and thereby the reproductive functions.